January 31, 2022
RegMed Investors’ (RMi) closing bell: I said, take the highs and sell them, there’s always a question of how long the upsides will last
January 28, 2022
RegMed Investors’ (RMi) closing bell: a daily reversal with a big positive sector close after a frustrating week for cell and gene therapy investors
January 27, 2022
RegMed Investors’ (RMi) closing bell: the costs of the roller-coaster sector rides
January 26, 2022
RegMed Investors’ (RMi) closing bell: I loved the smell of appreciation in the morning until the algorithms napalmed the cell and gene therapy sector
January 25, 2022
RegMed Investors’ (RMi) closing bell: wild volatility charges the slips and slides as the sector’s come-back collapses
January 24, 2022
RegMed Investors’ (RMi) closing bell: panic sector selling and then a major comeback
January 21, 2022
RegMed Investors’ (RMi) closing bell: sector trades accelerate risk aversion tumbles
January 20, 2022
RegMed Investors’ (RMi) closing bell: finally, the oversold were appreciative until the lower reverse unfolded
January 19, 2022
RegMed Investors’ (RMi) closing bell: a tightening cycle
January 18, 2022
RegMed Investors’ (RMi) closing bell: wipe-out
January 14, 2022
RegMed Investors’ (RMi) closing bell: a late session rebound, a bouncing sector rotates to close positive
January 13, 2022
RegMed Investors’ (RMi) closing bell: sector is still shackled by selling
January 12, 2022
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector went off the road and into a ditch, again
January 11, 2022
RegMed Investors’ (RMi) closing bell: sector volatility works to our favor in this market
January 10, 2022
RegMed Investors’ (RMi) closing bell: I’m not too early for the oversold party as I had written “it’s time to take a few risks”
January 6, 2022
RegMed Investors’ (RMi) closing bell: confluences, a junction of two positions of thought on the cell and gene therapy sector, BUY or SELL?
January 5, 2022
RegMed Investors’ (RMi) closing bell: another wave of unremitting selling hit the cell and gene therapy sector
January 3, 2022
RegMed Investors’ (RMi) closing bell: starting 2022 with a flash of confidence
December 22, 2021
RegMed Investors’ (RMi) closing bell: a positive and reasonable sector session to walk away to Christmas’ shortened week
December 21, 2021
RegMed Investors’ (RMi) closing bell: the pricing tug-of-war continues
December 20, 2021
RegMed Investors’ (RMi) closing bell: from the oversold mud to a draw in the daily share pricing tug-of-war
December 17, 2021
RegMed Investors’ (RMi) closing bell: a cell and gene therapy sector rotation in a frenetic and churning ascension
December 16, 2021
RegMed Investors’ (RMi) closing bell: it’s better to leave early to avoid the sector’s decline
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.